Cite
HARVARD Citation
Fujino, T. et al. (n.d.). Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation. European journal of cancer. pp. S78-S79. [Online].